0000930413-11-005490.txt : 20110816 0000930413-11-005490.hdr.sgml : 20110816 20110816122611 ACCESSION NUMBER: 0000930413-11-005490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110812 FILED AS OF DATE: 20110816 DATE AS OF CHANGE: 20110816 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buchbinder Aby CENTRAL INDEX KEY: 0001526633 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 111039310 MAIL ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD CITY: PISCATAWAY STATE: NJ ZIP: 08854 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 BUSINESS PHONE: 732-980-4500 MAIL ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 4 1 c66693_form4.xml OWNERSHIP DOCUMENT X0304 4 2011-08-12 0 0000727510 ENZON PHARMACEUTICALS INC ENZN 0001526633 Buchbinder Aby C/O ENZON PHARMACEUTICALS, INC. 20 KINGSBRIDGE ROAD PISCATAWAY NJ 08854 0 1 0 0 VP, Clinical Development Common Stock 2011-08-12 4 A 0 8000 0 A 59667 D Restricted Stock Units granted by the Issuer pursuant to its 2011 Stock Option and Incentive Plan and qualified under Rule 16b-3(d). Each unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in full on August 12, 2014, if the Reporting Person remains employed by the Issuer on such date, and do not have an expiration date; provided, however, that the vesting of 50% of the Restricted Stock Units shall be accelerated upon the Reporting Person's achievement of certain performance milestones determined by the Board of Directors of the Issuer. /s/ Andrew Rackear, Attorney-In-Fact 2011-08-16